Latest Bosentan Stories
WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc.
A new study has demonstrated no significant benefit of taking the drug bosentan for idiopathic pulmonary fibrosis (IPF).
MUMBAI, India, October 20, 2010 /PRNewswire-FirstCall/ -- Cipla, among the world's leading generic pharmaceutical companies, has introduced Pirfenidone in India under the brand name Pirfenex, for the treatment of IPF. A chronic progressive form of lung disease, IPF has average survival rates as low as 3-5 years which is less than many cancers.
SOUTH SAN FRANCISCO, Calif., Aug. 25 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRIÂ® for the company's epoprostenol for injection therapy.
SILVER SPRING, Md. and SOUTH SAN FRANCISCO, Calif., June 28 /PRNewswire/ -- The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc. today announced Actelion has been named the recipient of the 2010 Corporation of the Year Award.
WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while United Therapeutics' Tyvaso and Adcirca--launched in 2009--are each prescribed by more than half of surveyed pulmonologists in the specialized pulmonary arterial hypertension (PAH) center setting, Adcirca is much more widely used than Tyvaso among surveyed non-PAH-center physicians. The new Physician & Payer Forum...
NEW ORLEANS, May 17 /PRNewswire-FirstCall/ -- Actelion Ltd (SIX: ATLN) announced today that findings from the REVEALÂ® (Registry to EValuate Early And Long-term PAH Disease Management) Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension (PAH) according to data presented at the American Thoracic Society's (ATS) Annual International Conference.
SOUTH SAN FRANCISCO, Calif.
SOUTH SAN FRANCISCO, Calif., April 22 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc.
Research team reviews outcomes after 2 years of treatment with ambrisentan.
- A transitional zone between two communities containing the characteristic species of each.